#1 Clinical Trials Search in Europe

Protein C

Protein C, a naturally occurring anticoagulant in the human body, has been the subject of several clinical trials aimed at exploring its therapeutic potential in various medical conditions. These trials have investigated the use of Protein C concentrates and activated forms in treating conditions such as congenital Protein C deficiency, sepsis, acute pancreatitis, and stroke. The studies have focused on evaluating the safety, efficacy, and optimal dosing of Protein C-based treatments, with the goal of improving patient outcomes in these challenging medical scenarios.

Table of Contents

What is Protein C?

Protein C is a naturally occurring protein in our blood that plays a crucial role in preventing excessive blood clotting and reducing inflammation. When there’s a deficiency or malfunction of this protein, it can lead to serious health issues. To address this, medical researchers have developed a treatment called Protein C concentrate[1].

This treatment is available in different forms, including:

  • Freeze-dried Human Protein C Concentrate (also known as TAK-662)[1]
  • Protein C Concentrate (Human) Vapor Heated[3]
  • Activated Protein C (APC)[5]

Conditions Treated with Protein C

Protein C concentrate is used to treat several serious medical conditions, including:

  1. Congenital Protein C Deficiency: This is a rare inherited disorder where the body doesn’t produce enough Protein C, leading to an increased risk of blood clots[1].
  2. Sepsis and Septic Shock: These are life-threatening conditions caused by the body’s extreme response to an infection, often leading to organ failure[2].
  3. Purpura Fulminans: A rare, severe blood clotting disorder that can cause skin necrosis (death of skin tissue)[3].
  4. Coumarin-induced Skin Necrosis: A rare complication of anticoagulant therapy[3].
  5. Acute Pancreatitis: Severe inflammation of the pancreas[6].
  6. Acute Ischemic Stroke: A type of stroke caused by a blood clot blocking blood flow to the brain[7].

How Protein C Works

Protein C plays a dual role in the body:

  1. Anticoagulant: It helps prevent excessive blood clotting by regulating other proteins involved in the clotting process.
  2. Anti-inflammatory: It helps reduce inflammation, which is particularly important in conditions like sepsis[2].

When administered as a treatment, Protein C concentrate helps restore these functions in patients who have a deficiency or in conditions where these processes are impaired.

Forms of Protein C

Protein C is available in two main forms:

  1. Protein C Concentrate: This is the inactive form of the protein, which is activated by the body when needed[1].
  2. Activated Protein C (APC): This is the active form of the protein, ready to work immediately when administered[5].

How Protein C is Administered

Protein C is typically administered through intravenous (IV) injection or infusion. The dosage and duration of treatment can vary depending on the condition being treated and the patient’s response:

  • For congenital Protein C deficiency, it may be given as needed or as long-term supplementation[1].
  • In sepsis treatment, it’s often given as a continuous infusion for 72-96 hours[5].
  • For acute stroke, it has been studied as a single dose given within 9 hours of symptom onset[7].

Effectiveness of Protein C

The effectiveness of Protein C concentrate has been demonstrated in several studies:

  • In congenital Protein C deficiency, it has been shown to effectively treat and prevent episodes of purpura fulminans (a severe blood clotting disorder) and other thromboembolic events (blood clots)[4].
  • In sepsis, it has shown potential to improve blood flow in small blood vessels and organ function[5].
  • In acute pancreatitis, it may help reduce organ dysfunction[6].
  • In acute stroke, it’s being studied for its potential to reduce brain damage[7].

Safety and Side Effects

Protein C concentrate is generally considered safe, but like all medications, it can have side effects. The most significant concern is the risk of bleeding, which is carefully monitored during treatment[7].

Other potential side effects may include allergic reactions. However, severe allergic complications appear to be rare[2].

Ongoing Research

Research on Protein C is ongoing, with several clinical trials exploring its use in various conditions:

  • A study in Japan is evaluating the long-term safety and effectiveness of Protein C concentrate in patients with congenital Protein C deficiency[1].
  • Researchers are investigating its potential benefits in sepsis, acute pancreatitis, and acute stroke[5][6][7].

These studies aim to better understand how Protein C can be used to improve patient outcomes in these serious conditions.

Aspect Details
Conditions Studied Congenital Protein C Deficiency, Sepsis, Septic Shock, Acute Pancreatitis, Acute Ischemic Stroke
Forms of Protein C Used Protein C Concentrate, Activated Protein C
Administration Methods Intravenous injection, Continuous infusion
Primary Outcomes Measured Safety (adverse events, bleeding), Efficacy in treating specific conditions, Changes in organ function, Mortality rates
Secondary Outcomes Length of hospital stay, Improvements in condition-specific symptoms, Changes in microcirculation, Functional recovery scores
Safety Concerns Risk of bleeding, particularly intracranial hemorrhage
Potential Benefits Improved treatment of Protein C deficiency, Reduced organ dysfunction in sepsis, Potential neuroprotection in stroke

FAQ

  • What is Protein C and why is it being studied in clinical trials? Protein C is a naturally occurring anticoagulant in the human body. It's being studied in clinical trials because it has shown potential in treating various conditions, including congenital Protein C deficiency, sepsis, acute pancreatitis, and stroke. Researchers are investigating its ability to dissolve blood clots, reduce inflammation, and protect cells from damage.
  • What conditions are being targeted in these Protein C clinical trials? The clinical trials are targeting several conditions, including congenital Protein C deficiency, severe sepsis and septic shock, acute pancreatitis, and acute ischemic stroke. Each trial aims to evaluate the safety and effectiveness of Protein C-based treatments in these specific medical scenarios.
  • How is Protein C administered in these trials? In the trials, Protein C is typically administered intravenously. The specific dosage and duration vary depending on the study and condition being treated. For example, in some trials, it's given as a continuous infusion over several hours or days, while in others, it's administered as a combination of a bolus (quick dose) followed by an infusion.
  • What are the primary outcomes being measured in these Protein C trials? The primary outcomes vary depending on the specific trial and condition being studied. Common measures include safety assessments (such as the occurrence of adverse events or bleeding), changes in organ function scores, mortality rates, length of hospital stay, and improvements in condition-specific symptoms or complications.
  • Are there any risks associated with Protein C treatment in these trials? As with any medical treatment, there are potential risks associated with Protein C therapy. One of the main concerns is the risk of bleeding, particularly intracranial hemorrhage (bleeding in the brain). This is why many of the trials carefully monitor for bleeding events and other adverse effects. It's important to note that the trials are designed to assess both the safety and efficacy of the treatment.

Ongoing Clinical Trials on Protein C

  • Study on Venous Thromboembolism Prevention with Enoxaparin Sodium and Drug Combination for Patients Undergoing Total Hip or Knee Replacement

    Recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

  • Study on the Effects of Apixaban Absorption in Patients Undergoing Roux-en-Y Gastric Bypass Surgery

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Croatia Germany Italy Poland Spain

Glossary

  • Protein C: A naturally occurring anticoagulant protein in the blood that plays a role in preventing blood clots and reducing inflammation.
  • Congenital Protein C Deficiency: A rare inherited disorder where the body doesn't produce enough Protein C, leading to an increased risk of blood clots.
  • Sepsis: A life-threatening condition that occurs when the body's response to infection causes widespread inflammation and organ failure.
  • Purpura Fulminans: A rare, severe blood clotting disorder that can cause skin necrosis and organ failure, often associated with Protein C deficiency.
  • Coumarin-induced Skin Necrosis: A rare but serious side effect of certain blood thinners (coumarins) that can cause skin damage and death of skin tissue.
  • Thromboembolic Event: The formation of a blood clot in a blood vessel that breaks loose and is carried by the blood stream to plug another vessel.
  • Activated Protein C (APC): The active form of Protein C that has enhanced anticoagulant and anti-inflammatory properties.
  • Microcirculation: The circulation of blood in the smallest blood vessels, important for delivering oxygen and nutrients to tissues.
  • SOFA Score: Sequential Organ Failure Assessment score, used to track a patient's status during their stay in an intensive care unit.
  • Intracranial Hemorrhage (ICH): Bleeding that occurs inside the skull, a potential complication of some medical treatments.
  • Modified Rankin Scale (mRS): A scale used to measure the degree of disability in patients who have suffered a stroke or other neurological disabilities.
  • Barthel Index: A scale used to measure performance in activities of daily living (ADL) and mobility in patients with neuromuscular or musculoskeletal disorders.
  • National Institutes of Health Stroke Scale (NIHSS): A tool used to objectively quantify the impairment caused by a stroke, assessing various aspects of neurological function.

References

  1. https://clinicaltrials.gov/study/NCT06590974
  2. https://clinicaltrials.gov/study/NCT01705808
  3. https://clinicaltrials.gov/study/NCT00161720
  4. https://clinicaltrials.gov/study/NCT00157118
  5. https://clinicaltrials.gov/study/NCT01411670
  6. https://clinicaltrials.gov/study/NCT01017107
  7. https://clinicaltrials.gov/study/NCT00533546